Dyadic International (DYAI) Scheduled to Post Earnings on Thursday

Dyadic International (NASDAQ:DYAI) will be announcing its earnings results after the market closes on Thursday, March 28th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Dyadic International Price Performance

Shares of DYAI stock opened at $1.67 on Thursday. The stock has a market capitalization of $48.11 million, a PE ratio of -7.26 and a beta of 0.58. Dyadic International has a 1-year low of $1.19 and a 1-year high of $2.40. The business has a 50-day moving average of $1.44 and a 200 day moving average of $1.63.

Institutional Investors Weigh In On Dyadic International

Large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. purchased a new position in shares of Dyadic International during the second quarter valued at approximately $32,000. Captrust Financial Advisors purchased a new stake in shares of Dyadic International in the first quarter worth $45,000. Finally, Vanguard Group Inc. grew its stake in shares of Dyadic International by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 803,917 shares of the biotechnology company’s stock worth $1,294,000 after acquiring an additional 21,003 shares during the last quarter. Institutional investors own 15.58% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.